LABU241206P151000
- 27.32
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Reported Sunday, Gilead's Kite Highlights New Data Showcasing Yescarta's Curative Potential In Relapsed/Refractory Large B-Cell Lymphoma At ASH 2024
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304 Trial Met Primary Endpoint Of Overall Survival...
Weekly Buzz: Now THOSE are records!!
Wells Fargo's 'Value Equity' List: VZ, GM, TGT and More
Index Records are BACK for Friday Market While Unemployment Climbs | Live Stock
Thursday Indexes Pull back From Records While Bitcoin Sets New Ones | Wall Street Today
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
100k Bitcoin! Market Pulls Back After Records | Live Stock
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Incyte Gains Amid Takeover Speculation
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Looking At Gilead Sciences's Recent Unusual Options Activity
How Is The Market Feeling About Insmed?
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Screening For Black Friday Bargains In The Stock Market
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Gilead Sciences Ticks Upward for the Eight Consecutive Session
Looking Into Natera's Recent Short Interest
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump